Cardax IncOver The Counter Market:CDXI
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cardax Inc | 80.0 | 0.0x | --- |
Viropro Inc | 1.2K | 0.0x | --- |
MabCure Inc | 780.0 | 0.0x | --- |
AVAX Technologies Inc | 1.4K | 0.0x | --- |
Integrative Health Technologies Inc | 40.0 | 0.0x | --- |
Comera Life Sciences Holdings Inc | 9.2K | 0.0x | --- |
Company Information
Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.
Contact Information
- Headquarters
- SUITE 129, 2800 WOODLAWN DRIVEHONOLULU, HI, United States 96822
- Phone
- 808-457-1400
- Fax
- 808-237-5901
Executives
- Chairman of the Board, President, Chief Executive Officer
- David Watumull
- Chief Financial Officer, Chief Operating Officer, Assistant Treasurer, Company Secretary
- David Watumull
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $80.00 |
|---|---|
Revenue (TTM) | $500.7K |
Shares Outstanding | 802.5K |
Cardax Inc does not pay a dividend. | |
Beta | --- |
EPS | $-7.09 |
Book Value | $-12.84 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -628.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
